Skip to main content
Erschienen in: Supportive Care in Cancer 12/2007

01.12.2007 | Original Article

Symptom and medication profiles among cancer patients attending a palliative care clinic

verfasst von: Rachel P. Riechelmann, Monika K. Krzyzanowska, Aoife O’Carroll, Camilla Zimmermann

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with advanced cancer frequently experience distressful symptoms and receive numerous medications. We describe the symptomatology and medication profile of ambulatory cancer patients receiving exclusively supportive care at the Princess Margaret Hospital.

Materials and methods

This was a retrospective, cross-sectional study. We reviewed the charts of consecutive adult cancer patients attending palliative care clinics and who were no longer receiving cancer-directed therapy. From the medical records, we collected information about self-reported symptoms [screened for with the numerical Edmonton symptom assessment system (ESAS) scale; range, 0–10, with 10=worst symptom] and medication profiles. Summary statistics were used to describe the results.

Results

Two hundred fifty five patients met the inclusion criteria. The most frequent self-reported symptoms of any severity were fatigue (77%), pain (75%), and lack of appetite (66%). These were also the most severe symptoms: fatigue (median ESAS score=7), pain (median ESAS=5), and lack of appetite (median ESAS=5). The median number of medications per patient after consultation in the palliative care service was 6, and the most common classes of drugs prescribed were opioids (67%), laxatives/stool softeners (54%), corticosteroids (41%), and acetaminophen (41%). Palliative care physicians made at least one medication change in 75% of the patients, with the most frequent change being the addition of new medication(s); dexamethasone was the most commonly added individual drug (18% of the patients).

Conclusion

Among patients with advanced cancer not receiving antineoplastic therapy, the most frequent and severe symptoms were fatigue, pain, and lack of appetite. The medication profile represented drugs that could both alleviate and contribute to these symptoms. Audit of patient symptoms and medication prescription in palliative care may inform clinical practice and help the development of research specific to patient symptoms.
Literatur
1.
Zurück zum Zitat Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179PubMedCrossRef Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179PubMedCrossRef
2.
Zurück zum Zitat Mancini I, Lossignol D, Obiols M et al (2002) Supportive and palliative care: experience at the Institut Jules Bordet. Support Care Cancer 10:3–7PubMedCrossRef Mancini I, Lossignol D, Obiols M et al (2002) Supportive and palliative care: experience at the Institut Jules Bordet. Support Care Cancer 10:3–7PubMedCrossRef
3.
Zurück zum Zitat Elsayem A, Swint K, Fisch MJ et al (2004) Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 22:2008–2014PubMedCrossRef Elsayem A, Swint K, Fisch MJ et al (2004) Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 22:2008–2014PubMedCrossRef
4.
Zurück zum Zitat Riechelmann RP, Tannock IF, Wang L, Krzyzanowska MK (2006) Drug interactions in ambulatory cancer patients receiving cancer-therapy. Proc Am Soc Clin Oncol volume 24: abstract # 6129 Riechelmann RP, Tannock IF, Wang L, Krzyzanowska MK (2006) Drug interactions in ambulatory cancer patients receiving cancer-therapy. Proc Am Soc Clin Oncol volume 24: abstract # 6129
5.
Zurück zum Zitat Riechelmann RP, Moreira F, Smaletz O et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286–290PubMedCrossRef Riechelmann RP, Moreira F, Smaletz O et al (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56(3):286–290PubMedCrossRef
6.
Zurück zum Zitat Donnelly S, Walsh D, Rybicki L (1995) The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 11:27–32PubMed Donnelly S, Walsh D, Rybicki L (1995) The symptoms of advanced cancer: identification of clinical and research priorities by assessment of prevalence and severity. J Palliat Care 11:27–32PubMed
7.
Zurück zum Zitat Jenkins CA, Schulz M, Hanson J et al (2000) Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage 19:174–184PubMedCrossRef Jenkins CA, Schulz M, Hanson J et al (2000) Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage 19:174–184PubMedCrossRef
8.
Zurück zum Zitat Stromgren AS, Sjogren P, Goldschmidt D et al (2006) Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 31:199–206PubMedCrossRef Stromgren AS, Sjogren P, Goldschmidt D et al (2006) Symptom priority and course of symptomatology in specialized palliative care. J Pain Symptom Manage 31:199–206PubMedCrossRef
9.
Zurück zum Zitat Stromgren AS, Sjogren P, Goldschmidt D et al (2005) A longitudinal study of palliative care: patient-evaluated outcome and impact of attrition. Cancer 103:1747–1755PubMedCrossRef Stromgren AS, Sjogren P, Goldschmidt D et al (2005) A longitudinal study of palliative care: patient-evaluated outcome and impact of attrition. Cancer 103:1747–1755PubMedCrossRef
10.
Zurück zum Zitat Stromgren AS, Goldschmidt D, Groenvold M et al (2002) Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer 94:512–520PubMedCrossRef Stromgren AS, Goldschmidt D, Groenvold M et al (2002) Self-assessment in cancer patients referred to palliative care: a study of feasibility and symptom epidemiology. Cancer 94:512–520PubMedCrossRef
11.
Zurück zum Zitat Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef Nauck F, Ostgathe C, Klaschik E et al (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef
12.
Zurück zum Zitat Twycross RG, Bergl S, John S et al (1994) Monitoring drug use in palliative care. Palliat Med 8:137–143PubMed Twycross RG, Bergl S, John S et al (1994) Monitoring drug use in palliative care. Palliat Med 8:137–143PubMed
13.
Zurück zum Zitat Koh NY, Koo WH (2002) Polypharmacy in palliative care: can it be reduced? Singap Med J 43:279–283 Koh NY, Koo WH (2002) Polypharmacy in palliative care: can it be reduced? Singap Med J 43:279–283
14.
Zurück zum Zitat Mercadante S, Fulfaro F, Casuccio A (2001) Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 17:37–40PubMed Mercadante S, Fulfaro F, Casuccio A (2001) Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 17:37–40PubMed
15.
Zurück zum Zitat Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8:312–316PubMedCrossRef Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8:312–316PubMedCrossRef
16.
Zurück zum Zitat Zimmermann C, Seccareccia D, Clarke A et al (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987PubMedCrossRef Zimmermann C, Seccareccia D, Clarke A et al (2006) Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer 14:982–987PubMedCrossRef
17.
Zurück zum Zitat Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
18.
Zurück zum Zitat Bernhard J, Cella DF, Coates AS et al (1998) Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 17:517–532PubMedCrossRef Bernhard J, Cella DF, Coates AS et al (1998) Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med 17:517–532PubMedCrossRef
19.
Zurück zum Zitat Drummond SH, Peterson GM, Galloway JG et al (1996) National survey of drug use in palliative care. Palliat Med 10:119–124PubMed Drummond SH, Peterson GM, Galloway JG et al (1996) National survey of drug use in palliative care. Palliat Med 10:119–124PubMed
20.
Zurück zum Zitat Prue G, Rankin J, Allen J et al (2006) Cancer-related fatigue: a critical appraisal. Eur J Cancer 42:846–863PubMedCrossRef Prue G, Rankin J, Allen J et al (2006) Cancer-related fatigue: a critical appraisal. Eur J Cancer 42:846–863PubMedCrossRef
21.
Zurück zum Zitat Lundstrom SH, Furst CJ (2006) The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430–437PubMedCrossRef Lundstrom SH, Furst CJ (2006) The use of corticosteroids in Swedish palliative care. Acta Oncol 45:430–437PubMedCrossRef
22.
Zurück zum Zitat Ashbury FD, Madlensky L, Raich P et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285PubMed Ashbury FD, Madlensky L, Raich P et al (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285PubMed
Metadaten
Titel
Symptom and medication profiles among cancer patients attending a palliative care clinic
verfasst von
Rachel P. Riechelmann
Monika K. Krzyzanowska
Aoife O’Carroll
Camilla Zimmermann
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0253-8

Weitere Artikel der Ausgabe 12/2007

Supportive Care in Cancer 12/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.